Guangzhou Kang Liming Biotechnology
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.3m | Seed | |
$9.0m | Series A | ||
CNY300m | Series B | ||
CNY600m | Series C | ||
CNY560m Valuation: CNY3.0b | Series D | ||
Total Funding | $212m |
Related Content
Recent News about Guangzhou Kang Liming Biotechnology
EditCreative Bio is a biotechnology company specializing in early cancer screening and advanced genomic research. The company operates in the healthcare and life sciences market, providing cutting-edge solutions for both clinical and research applications. Creative Bio serves a diverse clientele, including hospitals, research institutions, and academic organizations. The company's business model revolves around the development and commercialization of highly sensitive diagnostic tests and automated laboratory equipment. Revenue is generated through the sale of diagnostic kits, laboratory instruments, and related services. Key products include the Human SDC2 Genomethylation test box and fully automated sample processors, which feature real-time display, data recording, UV light disinfection, and user-friendly touch screen interfaces. Creative Bio's innovative technologies enable accurate and efficient detection of cancer markers, contributing to early diagnosis and improved patient outcomes. The company also engages in scientific research projects, publishes academic journals, and participates in industry events to stay at the forefront of technological advancements.
Keywords: cancer screening, genomic research, diagnostic tests, automated systems, healthcare, biotechnology, SDC2 Genomethylation, PCR, T cell analysis, UV disinfection.